Company
Investment-firm
Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Related to
Sorrento Therapeutics
Sorrento Therapeutics is a biopharmaceutical company developing innovative therapies for cancer, autoimmune diseases and pain management.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Sub-Organizations2
TNK Therapeutics
TNK Therapeutics is a company focused on developing immunotherapy programs using chimeric antigen receptors.
Sector
Subsector
Location
Sorrento Therapeutics
Sorrento Therapeutics is a biopharmaceutical company developing innovative therapies for cancer, autoimmune diseases and pain management.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Similar Companies1000
Trigr Therapeutics
TRIGR Therapeutics is a privately-owned company that develops next-generation cancer therapies.
Sector
Subsector
Keywords
Location
Ziopharm oncology
ZIOPHARM Oncology is a biotechnology company developing gene therapy, cell therapy, and cancer immunotherapy products.
Sector
Subsector
Keywords
Location
total rounds
total raised
Virios Therapeutics
Virios Therapeutics is a clinical-stage biopharmaceutical company developing novel antiviral therapies for fibromyalgia and other diseases.
Sector
Subsector
Location
total rounds
total raised
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Sector
Subsector
Location
total rounds
total raised
Financials
Funding Rounds8
Number of Funding Rounds
Money Raised
Their latest funding was raised on 09.10.2019. Their latest round Post-IPO Equity
Ally Bridge Group
Ally Bridge Group is a global healthcare-focused investment group.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Investments5
Aardvark Therapeutics
Aardvark Therapeutics develops small molecule therapeutics for obesity and rare genetic metabolic disorders.
Sector
Subsector
Keywords
Location
total rounds
total raised
Celularity
Celularity is a clinical stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies.
Sector
Subsector
Location
total rounds
total raised
Celularity
Celularity is a clinical stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies.
Sector
Subsector
Location
total rounds
total raised
Co-Investors
Investors1
Number of lead investors
Number of investors
Ally Bridge Group
Ally Bridge Group is a global healthcare-focused investment group.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Acquisitions6
Ancora Medical Technology acquired by Sorrento Therapeutics
acquirer
date
type
Ancora Medical Technology
Ancora Medical is a privately held medical technology company.
Sector
Subsector
Keywords
Location
Virex Health acquired by Sorrento Therapeutics
acquirer
date
type
Virex Health
Virex is a biotech company revolutionizing global testing across various settings.
Sector
Subsector
Keywords
Location
total rounds
total raised
ACEA Therapeutics acquired by Sorrento Therapeutics
acquirer
date
price
ACEA Therapeutics
ACEA Therapeutics develops innovative treatments for life-threatening diseases.
Sector
Subsector
Location
Exits1
NantiBodyFc
NantiBodyFc is a healthcare company based in Cumming, Georgia.
Sector
Subsector
Keywords
Location
total rounds
total raised
People
Founders1
Henry Ji
Dr. Ji’s extensive knowledge of the industry in which we operate, as well as his unique role in our day-to-day operations as our Chief Executive Officer and President, allows him to bring to our board of directors a broad understanding of the operational and strategic issues we face. Dr. Ji also served as Sorrento’s Secretary from September 2009 to June 2011, Chief Scientific Officer from November 2008 to September 2012, and as its Interim Chief Executive Officer from April 2011 to September 2012. In 2002, Dr. Ji founded BioVintage, Inc., a research and development company focusing on innovative life science technology and product development, and has served as its President since 2002. From 2001 to 2002, Dr. Ji served as Vice President of CombiMatrix Corporation, a publicly traded biotechnology company that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics and nanotechnology. During his tenure at CombiMatrix, Dr. Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as Vice President, of Stratagene Corporation (later acquired by Agilent Technologies, Inc.) where he was responsible for novel technology and product licensing and development. In 1997, Dr. Ji co-founded Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999. Dr. Ji is the holder of several issued and pending patents in the life science field and is the sole inventor of Sorrento Inc.’s intellectual property covering the G-MAB® library technology. Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University.
current job
Henry Ji
Employee Profiles41
Haining Huang
President and cso, cytimm therapeutics
Robert Allen
Vice President Antiviral and oncolytic immunotherapy development
Brian Cooley
Senior vice president, devices and diagnostifcs
Activity
Recent News9
The graph reveals the ratio (%) of positive news articles in a chosen time range